Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Department of Pediatrics, Steel Memorial Hirohata Hospital, Himeji, Japan.
Pediatr Nephrol. 2023 Mar;38(3):757-762. doi: 10.1007/s00467-022-05687-y. Epub 2022 Jul 21.
Oligomeganephronia (OMN) is a rare congenital anomaly involving the kidney and urinary tract, characterized by decreased number and compensatory hypertrophy of the nephron. It is caused by abnormal kidney development during the embryonic period, especially in patients with low birth weight; however, the actual etiology and clinical features remain unknown. We aim to reveal the clinical and pathological characteristics, treatment, and outcome.
Ten patients diagnosed with OMN between 2013 and 2020 were retrospectively investigated. The data were presented as the median ± interquartile range, and statistical significance was set at p < 0.05.
The age at diagnosis was 14.1 years, the male-to-female ratio was 6:4, and only four cases were born with low birth weight. The estimated glomerular filtration rate (eGFR) was 62.2 mL/min/1.73 m. The glomerulus diameter of OMN patients was significantly larger (217 vs. 154 µm, p < 0.001) in OMN patients, and the number of glomeruli of OMN patients was lower (0.89 vs. 2.05/mm, p < 0.001) than the control group. Eight of the ten cases were identified by urinary screening. Nine patients were treated with renin-angiotensin system (RAS) inhibitors, following which proteinuria successfully decreased or disappeared. Their median eGFR was also stable, 53.3 mL/min/1.73 m.
As few symptoms can lead to OMN discovery, most patients were found during urine screening at school. Kidney dysfunction was observed in all patients at the time of kidney biopsy. Proteinuria has been significantly reduced and the decline rate of eGFR might be improved by RAS inhibitors. "A higher resolution version of the Graphical abstract is available as Supplementary information".
寡肾巨体症(OMN)是一种罕见的先天性肾和尿路异常,其特征为肾单位数量减少和代偿性肥大。它是由胚胎期肾脏发育异常引起的,尤其是在出生体重较低的患者中;然而,其实际病因和临床特征仍不清楚。我们旨在揭示其临床和病理特征、治疗方法和转归。
回顾性分析 2013 年至 2020 年间诊断为 OMN 的 10 例患者。数据以中位数(四分位间距)表示,统计学意义设为 p < 0.05。
诊断年龄为 14.1 岁,男女比例为 6:4,仅有 4 例患者出生时体重较低。估算肾小球滤过率(eGFR)为 62.2 mL/min/1.73 m。OMN 患者的肾小球直径明显更大(217 比 154 µm,p < 0.001),肾小球数量更少(0.89 比 2.05/mm,p < 0.001)。10 例中有 8 例通过尿筛查发现。9 例患者接受肾素-血管紧张素系统(RAS)抑制剂治疗,治疗后蛋白尿成功减少或消失。他们的中位 eGFR 也保持稳定,为 53.3 mL/min/1.73 m。
由于很少有症状可以导致 OMN 的发现,大多数患者是在学校的尿液筛查中发现的。所有患者在进行肾活检时均观察到肾功能障碍。RAS 抑制剂可显著减少蛋白尿,并可能改善 eGFR 的下降速度。